Clinical Trials

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07191249 2025-09-24

A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma (LTB-FL).

30 enrolled

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Follicular

NCT06793410 2025-06-05

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

Phase 2 Recruiting

100 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Papillomavirus Infections

NCT04668365 2025-04-25

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Phase 2 Suspended

59 enrolled

Phase 2 Enrolling by invitation

Congenital Abnormalities, Lymphoma, Large B-Cell, Diffuse

NCT06560879 2025-03-14

Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children with Leukemia

120 enrolled

GastrointestinalLymphoidOther hematologic neoplasm

Gastrointestinal Diseases, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03346096 2024-07-09

TEAM

50 enrolled

Phase 2 Not yet recruiting

Lymphoma

NCT06427213 2024-05-23

This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma

41 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT05963347 2023-09-01

Go-CHOP as the Frontline Therapy for PTCL

Phase 2 Recruiting

45 enrolled

Lymphoma, T-Cell, Peripheral

NCT04433156 2023-05-18

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

LymphoidOther hematologic neoplasm

Lymphoma, B-Cell, Marginal Zone

NCT05648019 2023-03-09

CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol

Phase 2 Recruiting

40 enrolled

Burkitt Lymphoma, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05385263 2022-05-26

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

20 enrolled

Lymphoma, B-Cell

NCT05286164 2022-04-15

Eltrombopag Treatment in Patients With Prolonged BM Toxicity After CART

30 enrolled

Lymphoma, B-Cell

NCT02733380 2020-04-01

Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma

20 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02533700 2020-03-10

CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL

106 enrolled

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT02747732 2019-04-23

Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

72 enrolled

Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03569696 2019-04-23

NivoM

50 enrolled

Lymphoma, B-Cell

NCT03022747 2017-01-16

Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01051154 2016-08-22

DHA-ALL

LymphoidOther hematologic neoplasm

72 enrolled

Malnutrition, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00750659 2016-04-20

Nilotinib Pre and Post Allogeneic Stem Cell Transplantation

LymphoidMyeloidOther hematologic neoplasm

24 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01079013 2016-04-20

Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

40 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT02507479 2016-04-20

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

LymphoidOther hematologic neoplasmPlasma cell

24 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00280878 2016-01-15

Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma

12 enrolled

Lymphoma, Lymphoma, Non-Hodgkin

NCT00163748 2016-01-08

Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

40 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT00163761 2016-01-08

Efficacy Study of Outpatient Therapy for Lymphoma

90 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT01164345 2015-12-03

Mozobil for Autologous Stem Cell Mobilization

20 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT01300156 2011-02-21

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

37 enrolled

Hodgkin Disease, Lymphoma, Recurrence

NCT00127569 2007-01-12

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Phase 2 Terminated

25 enrolled

LymphoidSarcoma

Castleman Disease, Sarcoma, Kaposi, HIV Infections

NCT00126243 2005-08-17

Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma

Phase 2 Terminated